title: [Medical and interventional treatment of right heart failure].
abstract: New pharmacological approaches are introduced for the treatment of chronic right heart failure which aim at reduced mortality. Riociguat is a new drug for the treatment of chronic thrombembolic pulmonary hypertension. Transcatheter valve interventions are established for treatment of pulmonary valve diseases and introduced as promising upcoming therapeutic options for tricuspid regurgitation. The management of acute right heart failure is supported by the miniaturization of mechanical circulatory support systems with percutaneous cannulation applicable in terms of "Bridge to Recovery" and "Bridge to Decision" concepts and effective long-term support, respectively.
authors.forename: Patrick
authors.initials: P
authors.lastname: Horn
authors.forename: Ralf
authors.initials: R
authors.lastname: Westenfeld
authors.forename: Hans R
authors.initials: HR
authors.lastname: Figulla
mesh_terms: D002317:Cardiovascular Agents / Q000627:therapeutic use; D006333:Heart Failure / Q000628:therapy*; D006349:Heart Valve Diseases / Q000628:therapy*; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D011720:Pyrazoles / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use
chemical_list: D002317:Cardiovascular Agents; D011720:Pyrazoles; D011743:Pyrimidines; C542595:riociguat